Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1984 6
1985 12
1986 12
1987 28
1988 18
1989 23
1990 41
1991 27
1992 27
1993 33
1994 34
1995 32
1996 29
1997 34
1998 30
1999 48
2000 50
2001 56
2002 69
2003 64
2004 87
2005 86
2006 138
2007 177
2008 224
2009 280
2010 315
2011 343
2012 339
2013 397
2014 397
2015 382
2016 387
2017 384
2018 334
2019 354
2020 415
2021 465
2022 478
2023 438
2024 249

Search Results

6,439 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, Tomczak P, Barthelemy P, Lee JL, Stus V, Ferguson T, Wiechno P, Gokmen E, Lacombe L, Gedye C, Perini RF, Sharma M, Peng X, Lee CH. Albiges L, et al. Lancet Oncol. 2023 Aug;24(8):881-891. doi: 10.1016/S1470-2045(23)00276-0. Epub 2023 Jul 11. Lancet Oncol. 2023. PMID: 37451291 Clinical Trial.
First-line ICIs in renal cell carcinoma.
Fiorentino V, Tralongo P, Larocca LM, Pizzimenti C, Martini M, Pierconti F. Fiorentino V, et al. Hum Vaccin Immunother. 2023 Aug 1;19(2):2225386. doi: 10.1080/21645515.2023.2225386. Epub 2023 Jul 3. Hum Vaccin Immunother. 2023. PMID: 37395601 Free PMC article. Review.
Renal cell carcinoma.
Rathmell WK, Martz CA, Rini BI. Rathmell WK, et al. Curr Opin Oncol. 2007 May;19(3):234-40. doi: 10.1097/CCO.0b013e3280ad4388. Curr Opin Oncol. 2007. PMID: 17414642 Review.
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, Choueiri TK, Saggi SS, McHenry MB, Motzer RJ. Albiges L, et al. ESMO Open. 2020 Nov;5(6):e001079. doi: 10.1136/esmoopen-2020-001079. ESMO Open. 2020. PMID: 33246931 Free PMC article. Clinical Trial.
Targeted therapies for renal cell carcinoma.
Posadas EM, Limvorasak S, Figlin RA. Posadas EM, et al. Nat Rev Nephrol. 2017 Aug;13(8):496-511. doi: 10.1038/nrneph.2017.82. Epub 2017 Jul 10. Nat Rev Nephrol. 2017. PMID: 28691713 Review.
Targeted therapy in metastatic renal carcinoma.
Mattei J, da Silva RD, Sehrt D, Molina WR, Kim FJ. Mattei J, et al. Cancer Lett. 2014 Feb 28;343(2):156-60. doi: 10.1016/j.canlet.2013.09.038. Epub 2013 Nov 13. Cancer Lett. 2014. PMID: 24239667 Review.
6,439 results